abstract |
The invention relates to leukotriene B4 antagonists of general formula (I) in which the contact of the chain O-(CH2)p-R1 can be situated at one of the free positions on the aromatic compound. R1 stands for CH2OH, COOR4, CONR5R6; R2 stands for H or an organic acid radical with 1-15 C atoms; R3 stands for H, C1-C14-alkyl, C3-C10-cycloalkyl, a C6-C10-aryl radical or a 5-6-link aromatic heterocyclic ring; R4 is H, C1-C10-alkyl, C3-C10-cycloalkyl, a C6-C10-aryl radical, CH2-CO-(C6-C10)aryl or a 5-6-link aromatic heterocyclic ring; A is a trans-, trans-CH=CH-CH=CH, a -CH2CH2-CH=CH- or a tetramethylene group; B is a C1-C10-alkylene group or the group (a) or (b); D is a direct bonding, oxygen, sulphur, -CC-, -CH=CR7, or a direct bonding together with B; Y is a C1-C8-alkyl, C3-C10-cycloalkyl; R5 and R6 are identical or different and are H; R7 is H, C1-C5-alkyl, chlorine, bromine; R8 is the same as R3; p is 1-6; m is 1-3, n is 2-5. When R4 is hydrogen. The invention also relates to their salts with physiologically compatible bases and their cyclodextrin clathrates. The leukotriene antagonists are effective dermatological products. |